GlassScriptPhysician profile
Lisa L Chan
NPI 1992860829
$11,043.78
in general payments reported to CMS, 2019-2025
45 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $1,365 · 2021: $2,185 · 2022: $1,636 · 2023: $1,227 · 2024: $1,463 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,294.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,009.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,319.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $882.57 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $698.96 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $633.92 | 2019-2025 | Jardiance, Stiolto Respimat |
| Pfizer INC. | $581.49 | 2019-2025 | |
| Amarin Pharma, INC. | $506.30 | 2019-2023 | |
| Glaxosmithkline, LLC. | $490.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $385.00 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $380.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Radius Health, INC. | $369.31 | 2019-2025 | Tymlos |
| Paratek Pharmaceuticals, INC. | $358.06 | 2020-2025 | Nuzyra, Xhance |
| Abbvie INC. | $334.05 | 2019-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.02 | 2021-2025 | Xifaxan |
| Mylan Specialty L.P. | $172.51 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.